Blue Trust Inc. Has $1.78 Million Holdings in Pfizer Inc. (NYSE:PFE)

Blue Trust Inc. increased its holdings in Pfizer Inc. (NYSE:PFE) by 14.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 61,517 shares of the biopharmaceutical company’s stock after buying an additional 7,958 shares during the period. Blue Trust Inc.’s holdings in Pfizer were worth $1,780,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. PFG Investments LLC lifted its position in shares of Pfizer by 2.6% during the 4th quarter. PFG Investments LLC now owns 206,418 shares of the biopharmaceutical company’s stock valued at $5,476,000 after acquiring an additional 5,157 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its stake in Pfizer by 7.0% in the fourth quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 46,758 shares of the biopharmaceutical company’s stock valued at $1,240,000 after purchasing an additional 3,078 shares in the last quarter. Regatta Capital Group LLC lifted its position in Pfizer by 10.5% during the fourth quarter. Regatta Capital Group LLC now owns 15,594 shares of the biopharmaceutical company’s stock worth $414,000 after purchasing an additional 1,480 shares during the period. Novare Capital Management LLC acquired a new stake in Pfizer during the fourth quarter worth about $228,000. Finally, Duncan Williams Asset Management LLC increased its holdings in Pfizer by 39.4% in the 4th quarter. Duncan Williams Asset Management LLC now owns 15,623 shares of the biopharmaceutical company’s stock valued at $414,000 after buying an additional 4,416 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

PFE stock opened at $26.86 on Tuesday. The company has a market capitalization of $152.19 billion, a P/E ratio of 36.29, a PEG ratio of 0.64 and a beta of 0.64. The company has a fifty day moving average price of $26.11 and a 200-day moving average price of $27.94. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.42. The business had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. Pfizer’s revenue for the quarter was up 31.2% compared to the same quarter last year. During the same period last year, the company earned ($0.17) EPS. As a group, equities analysts expect that Pfizer Inc. will post 2.94 EPS for the current year.

Pfizer Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be issued a $0.43 dividend. The ex-dividend date is Friday, January 24th. This is a boost from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a yield of 6.40%. Pfizer’s dividend payout ratio is presently 232.43%.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on PFE shares. UBS Group cut their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a report on Wednesday, January 8th. Guggenheim reduced their target price on Pfizer from $35.00 to $33.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. Bank of America reissued a “neutral” rating and set a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. Citigroup started coverage on Pfizer in a research note on Friday, October 25th. They issued a “neutral” rating and a $30.00 price objective on the stock. Finally, Truist Financial lowered their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Pfizer presently has a consensus rating of “Moderate Buy” and an average target price of $32.00.

Insider Buying and Selling at Pfizer

In other news, Director Scott Gottlieb acquired 1,000 shares of Pfizer stock in a transaction dated Wednesday, October 30th. The shares were bought at an average cost of $28.24 per share, with a total value of $28,240.00. Following the purchase, the director now owns 10,000 shares in the company, valued at $282,400. This trade represents a 11.11 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 0.06% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.